The MedZilla.com Employment Report for December, 2013: U.S. Unemployment Drops, Exciting New Developments in Biotech
Seattle, WA (PRWEB) December 12, 2013 -- The global outplacement firm Challenger, Grey & Christmas reported that recently December has been experiencing comparatively small job-cut totals since the end of the recession. They also mentioned that the November job cuts were 21 percent lower than the same month last year and lower than employers were expecting. (challengergray.com, 12/5/13) This has been especially good news for many companies attempting to branch out in research and development areas.
"When people hear the phrase 'gains in Healthcare' they may automatically assume the benefits will be confined to the traditional patient care areas that are presented to the public. Clearly those are vital areas which will also see the benefit. However, as technology has become more of an intrinsic part of the way we research in the Healthcare Industry, gains within that industry have further reaching ramifications than merely within doctor's offices and hospitals. Biotechnology, Pharmaceutical technology and many other areas of sales, research and business will also see gains as a result," says Del Johnston, Manager of Client Relations at MedZilla.com.
With the availability of Gardasil and Cervarix helping to protect women against cervical cancers (cdc.gov/hpv/vaccine.html), researchers in the biotech industry have been looking into branching out and looking into the potentials of what other cancers might also be prevented with a vaccine. The concept of a series of vaccinations which could lower the risk in patients of some of the most deadly cancers has many researchers very interested in what potential might exist.
In central Massachusetts, Eric von Hofe is now preparing to have his data reviewed from studies he has been doing for the development of a breakthrough breast cancer vaccine. His tiny eleven person company, a subsidiary of the Toronto-based Generex Biotechnology Corp., Antigen Express Inc., has been developing an anti-scarring action, using a gene-blocking mechanism called RXI-109. The research has already progressed on to Phase II trials and is seeking additional funding.
They are courting regulator's approval to begin testing in 2014 for other disorders. According to spokeswoman Tamara McGrillen, this new gene-blocking technology could be a real breakthrough for multiple disorders, ranging from breast cancer to Hepatitis C. While it could be another four to five years before the company gets to the point of FDA approval for getting a drug out to the actual market, that is not an uncommon timeline to ensure public safety. (telegram.com, 12/8/13)
John Burkhardt Managing Director of MedZilla.com weighs in. "This is just fantastic. Preventative medicine is a really feel-positive way to get work done in R&D. When you're out there in the field doing Pharmaceutical Sales, as well, there's a good feeling about giving people something that keeps them healthy. Device Sales is another great field that is growing all the time and you can feel great about contributing to these innovative new technologies. It's difficult not to get excited talking about this stuff to people all around you, not to mention your clients!"
**********************************************************************************************************
About MedZilla.com:
Established in mid-1994, MedZilla is the original and leading web site to serve career and hiring needs for professionals and employers in biotechnology, pharmaceuticals, medicine, science and healthcare. The MedZilla jobs database contains about 7,500 open positions. The resume database currently contains over 295,000 resumes with 26,500 less than three months old. These resources have been characterized as the largest, most comprehensive databases of their kind on the web in the industries served.
MedZilla(R) is a Registered Trademark owned by MedZilla Inc. Copyright (C)MedZilla, Inc. Permission is granted to reproduce and distribute this text in its entirety, and if electronically, with a link to the URL http://www.medzilla.com. For permission to quote from or reproduce any portion of this message, please contact MedZilla, Inc. at press(at)medzilla(dot)com
Press Inquiries
Contact: MedZilla, Inc.
Phone: (360) 657-5681
press(at)medzilla(dot)com
###
Del Johnston, MedZilla, Inc., http://www.medzilla.com, +1 (360) 657-5681, [email protected]
Share this article